StockNews.com started coverage on shares of Genocea Biosciences (NASDAQ:GNCA – Free Report) in a report published on Tuesday morning. The brokerage issued a sell rating on the biotechnology company’s stock.
Genocea Biosciences Price Performance
The firm has a market cap of $6,000.00, a P/E ratio of 0.00 and a beta of 1.61. The company has a debt-to-equity ratio of 0.24, a current ratio of 1.35 and a quick ratio of 1.35. Genocea Biosciences has a 1-year low of $0.00 and a 1-year high of $0.00.
About Genocea Biosciences
Read More
- Five stocks we like better than Genocea Biosciences
- How to Find Undervalued Stocks
- Comprehensive PepsiCo Stock Analysis
- ETF Screener: Uses and Step-by-Step Guide
- CSX Co.: The Railroad Powering Ahead with an Earnings Beat
- How to Choose Top Rated Stocks
- 3 Steel Stocks Could Soar on New China Tariffs
Receive News & Ratings for Genocea Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genocea Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.